Jan van de Winkel

CEO

Chairman

HOOKIPA Pharma Inc.

Equibles does not estimate personal net worth.

Get an email with a short summary when Genmab A/S publishes a filing, an earnings call transcript or a press release.

About Jan van de Winkel

Jan van de Winkel is recorded as CEO at Genmab A/S (GMAB) and Chairman at HOOKIPA Pharma Inc.. The newest filing on record that lists Jan van de Winkel as Chairman at HOOKIPA Pharma Inc. is dated April 26, 2024. HOOKIPA Pharma Inc. reported in an 8-K filed August 30, 2024 that Jan van de Winkel resigned as director, effective August 30, 2024. Jan van de Winkel has spoken on 25 earnings calls and 2 other investor events across 1 company, most recently for Genmab A/S on November 5, 2026. Genmab A/S is classified in the Biotechnology industry within the Healthcare sector. HOOKIPA Pharma Inc. is classified in the Biotechnology industry within the Healthcare sector.

“On August 27, 2024, Jan van de Winkel, Ph.D., notified HOOKIPA Pharma Inc. (the “Company”) of his resignation as a director of the Company, effective as of August 30, 2024 at 12:00 p.m. Eastern Time (the “Effective Time”).”

HOOKIPA Pharma Inc. Form 8-K, filed August 30, 2024 · Read the filing

Jan van de Winkel on recent calls

“Good to have you all with us, and welcome to GenMap's results call for the first nine months of 2026. Joining me are our Chief Financial Officer, Anthony Pagano, and our Chief Commercial Officer, Brad Bailey.”

CEO, Publication of the Interim Report for the First Nine Months 2026 (after 5:00 PM CET) · November 5, 2026

“Maybe taking a step back and then looking at 2026. So far, so good. A strong first half, as you saw at our Q2 results, both operationally and financially, where we upped our guidance, especially the top line, where it was driven primarily by DASLEX, but importantly also by Epkinney.”

CEO, Bank of America Global Healthcare Conference · September 22, 2026

“I'll be delighted to be here, and I'm delighted to update you all on the progress of the company because we have made a lot of progress. We have now nine medicines where we generate revenue from.”

CEO, Morgan Stanley 24th Annual Global Healthcare Conference · September 15, 2026

“With me today is our chief financial officer, Anthony Pagano, our chief commercial officer, Brad Bailey, and our chief medical officer, Taya Mahdi. For the Q&A, we will be joined by our chief development officer, Judith Klimovsky.”

CEO, Earnings conference call (announced in 6-K) · August 6, 2026

“With me today is our Chief Financial Officer, Anthony Pagano, and our Chief Commercial Officer, Brad Bailey. For the Q&A, we will be joined by our Chief Medical Officer, Tai Yamadi, and our Chief Development Officer, Judith Klimovsky.”

CEO, Earnings conference call (announced in 6-K) · May 7, 2026

Affiliation history

Genmab A/S (GMAB)
CEO

Source not stated

Current
HOOKIPA Pharma Inc.

Chairman

Proxy statement

Current
Start not stated–present

Last confirmed April 26, 2024